Kingsview Wealth Management LLC Invests $542,000 in Organon & Co. (NYSE:OGN)

Kingsview Wealth Management LLC bought a new stake in shares of Organon & Co. (NYSE:OGN) during the fourth quarter, Holdings Channel.com reports. The fund bought 36,323 shares of the company’s stock, valued at approximately $542,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Cetera Investment Advisers grew its holdings in Organon & Co. by 2.4% in the second quarter. Cetera Investment Advisers now owns 58,599 shares of the company’s stock valued at $1,213,000 after purchasing an additional 1,378 shares during the period. SG Americas Securities LLC lifted its position in shares of Organon & Co. by 161.1% during the 3rd quarter. SG Americas Securities LLC now owns 22,689 shares of the company’s stock valued at $434,000 after buying an additional 14,000 shares in the last quarter. Ritholtz Wealth Management purchased a new position in shares of Organon & Co. during the 3rd quarter valued at approximately $356,000. SeaCrest Wealth Management LLC grew its stake in Organon & Co. by 32.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 16,218 shares of the company’s stock valued at $310,000 after acquiring an additional 3,999 shares during the period. Finally, nVerses Capital LLC purchased a new stake in Organon & Co. in the 3rd quarter worth $260,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

NYSE OGN opened at $14.70 on Thursday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock’s 50 day simple moving average is $15.33 and its 200-day simple moving average is $17.54. The company has a market cap of $3.79 billion, a PE ratio of 2.92, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Analyst Ratings Changes

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.